The global infectious disease therapeutics market size was valued at USD 67.1 billion in 2022 and expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2023 to 2030. The rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for the development of new drugs are likely to be the factors responsible for the growth of this market.
The market is likely to witness the patent expiration of many drugs during the forecast period. The expiry of patents results in the availability of generic drugs, which have the same drug constitution as branded drugs but are available at a very low price. Also, physicians prescribe these drugs to patients as they are cost-effective. Furthermore, a positive reimbursement scenario that covers the diagnosis and treatments of these disorders is expected to propel the market growth. Key players are also developing new products to treat infectious diseases and receiving approvals to commercialize their products. For instance, In December 2022, the FDA approved Sunlenca, developed by Gilead Sciences, to treat HIV-1 infection in adults with multi-drug resistant HIV-1.
However, lack of awareness about these disorders and low adoption of treatments are factors expected to restrain the growth in the coming years. Africa and Asia have a high incidence of infectious disorders and a low penetration rate of treatments for the same.
Based on disease type, the market is segmented into HIV, malaria, hepatitis, influenza, human papillomavirus (HPV), and tuberculosis. The HIV segment held the largest revenue share of 31.6% in 2022. The increasing prevalence of HIV, rising funding activities for patients who have HIV, increasing supply of free HIV self-test kits in African countries, and raising awareness campaigns around the globe are the key factors responsible for the largest share held by this segment. According to the World Health Organization (WHO), HIV remains a significant global public health issue, claiming 40.4 million lives with ongoing transmission globally.
In 2022, the hepatitis therapeutics segment held the second-largest share in the top six market for infectious disease therapeutics. The rising prevalence of hepatitis, increasing clinical trial activities for the launch of new drugs, and a growing number of initiatives to increase the adoption of drugs are expected to be the factors responsible for the significant share held by this segment. Moreover, WHO aims to test 90% and treat 80% of the people suffering from HBV and HCV by 2030 through its Global Health Sector Strategy on viral hepatitis, which is further expected to contribute to the growth of this segment.
The HPV segment is expected to grow at the fastest CAGR of 8.1% during the forecast period. Major factors that are responsible for its growth include the increasing prevalence of HPV and the low cost of drugs that are used in the treatment of this infection. According to WHO, HPV is the most common sexually transmitted infection, and most sexually active individuals are likely to be infected with this virus at least once in their lifetime. HPV infection does not have any treatment. However, the symptoms of HPV, such as genital warts, can be treated using various anti-infective drugs. In January 2023, India's Serum Institute of India launched the first made-in-India Quadrivalent Human Papillomavirus vaccine, 'CERVAVAC.' The vaccine results from a partnership between the institute, DBT, BIRAC, and the Bill and Melinda Gates Foundation.
The hospital's segment held the largest revenue share of 54.5% in 2022. The increasing number of emergency hospital visits reporting infectious diseases is a significant growth factor for the market. Hospitals offer reimbursement policies and facilities through insurance companies, providing attractive opportunities for the growth of this segment. These facilities prevent patients from traveling to multiple centers, enhancing the hospital sector's offerings. According to the Centers for Disease Control and Prevention (CDC), 9 million illnesses, 4 million doctor visits, 10,000 hospitalizations, and 5,000 fatalities were noted during the 2021–2022 influenza season.
The clinics segment is expected to grow at the fastest CAGR of 7.7% during the forecast period. This is attributed to the high demand for outpatient care, the availability of advanced diagnostic and therapeutic facilities, and the rising awareness of preventive measures among the public. Clinics offer various services for infectious disease patients, such as screening, testing, vaccination, counseling, and treatment. They also provide access to specialized care for complex and rare infections, such as HIV/AIDS, tuberculosis, hepatitis, and COVID-19. Clinics are also involved in clinical trials and research activities to evaluate the safety and efficacy of new drugs and vaccines for infectious diseases. This has contributed to the growth of this segment.
North America dominated the market with the largest revenue share of 39.9% in 2022. The increasing prevalence of such disorders and favorable reimbursement scenarios are key factors likely to propel the region's demand for infectious disease therapeutics. Furthermore, the presence of many manufacturers in the U.S. and increasing numbers of clinical trials for developing new treatment drugs are expected to contribute to the large market share held by this region. Major factors that are likely to propel the growth of this market include the increasing rate of treatment & diagnosis of infectious diseases and rising funding activities to support the development of new drugs. According to the Centers for Disease Control and Prevention, in the U.S., 41,917 death cases were reported due to influenza and pneumonia in 2021.
Asia Pacific is estimated to grow at the fastest CAGR of 8.3% during the forecast period. The high prevalence of HIV, malaria, TB, and other infections; the increasing incidence of these conditions; and rising expenditure on the prevention and diagnosis of infectious diseases are likely to be the key factors responsible for the growth of this market. Furthermore, increasing the focus of governments of various countries on the prevention of infections and raising funds to increase the adoption of treatments for infectious diseases are expected to propel the market during the forecast period. In June 2023, INVEX Health announced to launch of India's first oral HIV self-test. The third-generation HIV test currently employs oral fluid rather than blood is the saliva-based Morcheck test. It checks for HIV types 1 and 2.
The majority of the people suffering from these infections are living in Africa. The WHO African Region has a high share of the malaria burden globally, with 95% of cases and 96% of malaria deaths in 2021. Children under 5 accounted for 80% of all deaths. Various initiatives focusing on disease prevention are being undertaken in the region. Furthermore, government, private, and nonprofit organizations are focusing on increasing the management of these diseases. For instance, Novartis supplies free drugs to patients suffering from malaria in the African region.
Some of the significant players operating in this market are Novartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., Merck & Co., Inc., and Boehringer Ingelheim GmbH. Incessant regulatory approval for the commercial availability of anti-infectives is likely to be the key factor attributing to the share of these players in the top six infectious disease therapeutics market. In June 2022, NRG Therapeutics raised $18.3 million in Series A funds to develop mitochondrial therapeutics for neurodegenerative diseases like Parkinson's and ALS. The following are some of the major participants in the global infectious disease therapeutics market:
Janssen Pharmaceutical, Inc.
F. Hoffmann-La Roche Ltd.
BioCryst Pharmaceuticals Inc.
Merck & Co., Inc.
Boehringer Ingelheim GmbH.
Market size value in 2023
USD 71.5 billion
Revenue forecast in 2030
USD 115.2 billion
CAGR of 7.1% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Disease type, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Novartis AG; Gilead; GlaxoSmithKline plc; Janssen Pharmaceutical, Inc.; F. Hoffmann-La Roche Ltd.; BioCryst Pharmaceuticals, Inc.; Merck & Co., Inc.; Boehringer Ingelheim GmbH.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global infectious disease therapeutics market report based on disease type, end-use, and region:
Disease Type Outlook (Revenue, USD Billion, 2018 - 2030)
End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East and Africa
b. The global infectious disease therapeutics market size was estimated at USD 67.1 billion in 2022 and is expected to reach USD 71.4 billion in 2023.
b. The global infectious disease therapeutics market is expected to grow at a compound annual growth rate of 7.1% from 2023 to 2030 to reach USD 115.2 billion by 2030.
b. HIV dominated the infectious disease therapeutics market with a share of 31.5% in 2022 due to the increasing prevalence of HIV, rising funding activities for patients suffering from HIV, increasing supply of free HIV self-test kits in African countries, and rising awareness campaigns
b. The key players operating in the infectious disease therapeutics market include Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH. among others
b. Key factors that are driving the market growth include rising funding activities for the development of new drugs; increasing prevalence of infectious diseases; growing awareness activities for diagnosis & treatment of these diseases; and rising number of patent expirations of infectious disease drugs.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."